A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus-infected patients

Liver Transplantation

Volumn 14, Issue 8, 2008, Pages 1194-1198

  Tateo, Mariagrazia ^a,b,c,d   Sebagh, Mylène ^a,b,c   Bralet, Marie Pierre ^a,b,c   Teicher, Elina ^a   Azoulay, Daniel ^a   Mallet, Vincent ^c,e   Pol, Stanislas ^c,e   Castaing, Denis ^a,b,c   Samuel, Didier ^a,b,c   Duclos Vallée, Jean Charles ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b Universite Paris Sud   (France)

^c INSERM   (France)

^d UNIVERSITY OF BARI   (Italy)

^e AP HP Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACENOCOUMAROL; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CADAVER DONOR; CASE REPORT; DOPPLER ECHOGRAPHY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HYPERPLASIA; LIVER NODULAR REGENERATIVE HYPERPLASIA; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS LOAD;

EID: 49649101086     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21493     Document Type: Article

References (20)

1. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:187-192.
2. Podevin P, Spiridon G, Terris B, Chauvelot-Moachon L, Guillevin L, Chaussade S, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006;20:313-315.
3. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007;21:1066-1068.
4. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007;102:2536-2540.
5. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-182.
6. Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore) 1980;59:367-379.
7. Gris JC, Toulon P, Brun S, Maugard C, Sarlat C, Schved JF, et al. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb Haemost 1996:76:38-45.
8. Klein SK, Slim EJ, de Kruif MD, Keller TT, ten Cate H, van Gorp EC, Brandjes DP. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005;63:129-136.
9. Feffer SE, Fox RL, Orsen MM, Harjai KJ, Glatt AE. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J 1995;88:1126-1130.
10. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003;9:325-331.
11. Koppel K, Bratt G, Lund B, Frederikson EL, Sandström E. A hypercoaguable state associated with protease inhibitor containing highly active antiviral therapy (HAART) (PIHAART) in HIV-1 infection. AIDS 2000;14(suppl):S72.
12. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS 2007;21:1494-1495.
13. Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol 2001;36:417-422.
14. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005;11: 627-634.
15. Radomski JS, Chojnacki KA, Moritz MJ, Rubin R, Armenti VT, Wilson GA, et al. Results of liver transplantation for nodular regenerative hyperplasia. Am Surg 2000;66: 1067-1070.
16. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006;44(suppl): S132-S139.
17. Duclos-Vallee JC, Vittecoq D, Teicher E, Feray C, Roque-Afonso AM, Lombes A, et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005;42:341-349.
18. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006;6:2983-2993.
19. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407-417.
20. Devarbhavi H, Abraham S, Kamath PS. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl 2007;13:1552-1556.